KospicyKorean filings in English
Filings / Celltrion

Material Information for Investment Decisions — CTP13SC — Part1&2

Celltrion · 투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 유럽 임상 3상 시험계획 승인(Part1&2) (류마티스 관절염 환자))

8-KKOSPI · 068270 Filed 2026-11-02Korean original on DARTCelltrion financials

Event brief numbers checked

Celltrion wins EMA approval for Phase 3 trial of CT-P13 SC (Zymfentra) in rheumatoid arthritis

Celltrion reported that the European Medicines Agency (EMA) approved Part 1 and Part 2 of its Phase 3 clinical trial application for CT-P13 SC (Zymfentra) at the same time. The patients have moderately to severely active rheumatoid arthritis. The randomized, placebo-controlled, double-blind trial will enroll 296 subjects for a 52-week treatment period. The primary endpoint is superiority over placebo in ACR50 clinical response at Week 12.

Subjects
296
Treatment period
52 weeks
Primary endpoint
ACR50 response at Week 12 vs placebo
EU CT number
2026-526538-15
Approval probability cited by the filing (industry statistic)
About 10%
Clinical trial application to EMA (local time) 2026-07-24 · EMA approval (local time) 2026-10-30 · Fact confirmation in CTIS 2026-11-02

Full translation

Material Management Matters Relevant to Investment Decisions

1. TitleApproval of European Phase 3 Clinical Trial Application (Part 1 & 2) for CT-P13 SC (Zymfentra) (Patients with Rheumatoid Arthritis)
2. Key Details※ Investment Caution: Statistically, the probability that an investigational drug receives final approval as a medicinal product is known to be about 10%. The clinical trial and marketing authorization processes may produce results that do not meet expectations. As a result, the Company may change or abandon its commercialization plans. Investors should comprehensively consider the investment risks disclosed in ad-hoc disclosures, business reports, and other filings, and invest with caution. 1) Clinical trial title: <br><br> - A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Injection of CT-P13 (CT-P13 SC) in Patients with Moderately to Severely Active Rheumatoid Arthritis 2) Clinical trial phase: <br><br> - Global Phase 3 clinical trial 3) Target disease (indication): <br><br> - Rheumatoid Arthritis (RA) 4) Clinical trial application date, approval date, and authority: <br><br> - Application date: 2026-07-24 (local time) <br><br> - Approval date: 2026-10-30 (local time) <br><br> - Authority receiving the application: European Medicines Agency (EMA) 5) Clinical trial registration number: <br><br> - EU CT number: 2026-526538-15 6) Clinical trial objective: <br><br> - To demonstrate the superiority of CT P13 SC over placebo in terms of efficacy, as determined by clinical response according to ACR50 at Week 12. 7) Clinical trial method: <br><br> - Subjects: 296 <br><br> - Trial period: 52-week treatment period <br><br> - Trial design: Randomized, placebo-controlled, double-blind, parallel-group, Phase 3 clinical trial 8) Future plans: <br><br> - CT-P13 SC (Zymfentra) is the subcutaneous formulation of Remsima IV, an infliximab biosimilar. The Company developed it to improve patient dosing convenience and to provide more treatment opportunities. <br><br> - CT-P13 SC completed Phase 3 clinical trials in adult patients with ulcerative colitis and Crohn's disease, and obtained marketing authorization in multiple countries, including the United States and Europe. The Company expects that this Phase 3 rheumatoid arthritis trial will make it possible to provide treatment opportunities to more patients, in addition to the adult ulcerative colitis and Crohn's disease indications. 9) Other matters: <br><br> - Due to the revision of the EU Clinical Trials Regulation, from 2023-01-31 the European clinical trial application/approval procedure has been divided into Part 1 (assessment of clinical design and research methods) and Part 2 (assessment of clinical sites and conduct). A clinical trial can proceed only after both Part 1 and Part 2 receive final approval. Please note that this disclosure concerns the simultaneous approval of Part 1 and Part 2 of the European Phase 3 clinical trial application.
3. Date of board of directors resolution (decision) or date of fact confirmation2026-11-02
- Attendance of independent (outside) directors*Present (persons)-
Absent (persons)-
- Attendance of auditor (audit committee member who is not an independent (outside) director)-
4. Other important matters relevant to investment decisions
- The above date of fact confirmation is the date on which the Company confirmed the approval of the clinical trial application in CTIS (Clinical Trial Information System). - Please note that this disclosure concerns the simultaneous approval of Part 1 and Part 2 of the European Phase 3 clinical trial application. - The Company plans to use the contents of this disclosure in its future press releases and IR materials.
※ Related disclosure2026-07-24 Material Management Matters Relevant to Investment Decisions (Application for European Phase 3 Clinical Trial (Part 1 & 2) for CTP13 SC (Zymfentra) (Patients with Rheumatoid Arthritis))